AB0491 Fatigue is an independent variable predicting physical function and DAS-28 remission for patients with rheumatoid arthritis treated with intravenously administered golimumab: results from phase 3, placebo controlled clinical trial

Objectives To evaluate the association of fatigue with physical function and disease activity in patients with rheumatoid arthritis (RA), and the impact of treatment with intravenously administered golimumab (GLM) on fatigue using data from the Phase III clinical trial GO-FURTHER. Methods GO-FURTHER was a multicenter, randomized, placebo-controlled study. Adult patients with active RA despite MTX therapy were randomized to placebo + MTX (placebo group) or GLM 2mg/kg plus MTX (GLM group) at week 0, 2, and every 8 week thereafter. Patients in placebo group with